Abstract 286P
Background
Recurrent tumors on MRI described as intermediate T2 signal intensity and ADC quantitative values derived from diffusion sequences are prone to discrepancy. In post surgical setting of oral cavity ADC values are prone to artifacts limiting its utility. This investigation aims to build a decision model using quantitative robust parameters derived from MR imaging.
Methods
Four lesion quantitative parameters ( quantitative T2 lesion signal, T2 lesion/muscle signal ratio, T2 lesion /Tongue signal ratio and ADC values) were assessed in 68 lesions (54 malignant,14 benign). Classification analysis was performed using L1 regularization of features in a Logistic regression, Statistical feature selection methods like ANOVA f-value and chi square and lastly a Entropy based feature selection using decision tree. Results include the probability for malignancy for every descriptor combination in the classification tree. Area under the curve (AUC) used as the statistical parameters to find model efficiency was calculated using software "R".
Results
Logistic regression based classifier could predict the probability of cancer based on T2 based features alone. ADC was not found helpful in predicting the disease. Both scores obtained from ANOVA and Chi-square have a different assumptions about distributions of input feature values and output probabilities, but yielded different scores. Both methods point to T2 as most significant in predicting output probabilities of cancer. Lastly, the decision tree showed T2 based features in addition to ADC provide maximum diagnostic value in determining cancer in patients. The area under the curve of the ROC was .940 for additive T2 and ADC and only 0.74 for ADC values alone. The signal ratios (T2 lesion/muscle signal ratio and T2 lesion /Tongue signal ratio) have an AUC 0.96.
Conclusions
Though each method of feature selection has certain shortfalls due to the assumptions but results demonstrate T2 feature outranking all others, indicating its high predictive power in determining the probability of disease. It is therefore possible to train predictive robust models based on T2 quantitative features with high level of accuracy and precision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session